Dark

Check out our Level2View

CLSD
Clearside Biomedical, Inc. Common Stock
stock NASDAQ

Inactive

Nov 28, 2025

0.4100USD-26.955%(-0.1513)2,768,773

Pre-market

0.00USD-100.000%(-0.56)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Dec 21, 2021

08:12AM EST Clearside Reports Positive Safety Results From OASIS Phase RTTNews

07:31AM EST Clearside Biomedical Announces Positive Safety Results From OASIS Phase 1/2a Trial Of CLS-AX For Wet AMD; Stock Up RTTNews

07:08AM EST Clearside Biomedical Announced Suprachoroidal Injection of CLS-AX 0.1 mg Dose Well-Tolerated in Cohort 2 with No Treatment Related Adverse Events; Supports Advancement to Cohort 3 Benzinga

07:05AM EST - Suprachoroidal Injection of CLS-AX 0.1 mg Dose Well-Tolerated in Cohort 2 with No Treatment Related Adverse Events - Consistent Safety Profile Observed in Cohorts 1 and 2 Supports Advancement to Cohort 3 -- Webcast and Conference Call Today at 8:30 A.M. ET Hosted by Management and Including Key Opinion Leader, Peter Kaiser, M.D. - GlobeNewswire Inc

Dec 14, 2021

08:22AM EST The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks Benzinga

Dec 13, 2021

04:05PM EST Clearside Biomedical, Inc.(Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS), announced today that the Company will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021. GlobeNewswire Inc

Nov 23, 2021

10:33AM EST Clearside Biomedical Sponsored Study Titled 'Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study' Posted To ClinicalTrials.gov; Study Is Recruiting Benzinga

Nov 16, 2021

07:14AM EST Clearside Biomedical Highlights Featuring Of XIPERE Inn Multiple Presentations At American Academy Of Ophthalmology 2021 And American Uveitis Society Meetings Benzinga

07:05AM EST Clearside Biomedical, Inc.(NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS), announced today that multiple presentations were given at the American Academy of Ophthalmology (AAO) 2021, which took place November 12 - 15, 2021 in New Orleans, LA. GlobeNewswire Inc

Nov 12, 2021

07:47AM EST The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares Benzinga

Nov 11, 2021

07:05AM EST Clearside Biomedical, Inc.(NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS), announced today that it will participate in the following investor events, which will each be held in a virtual meeting format: GlobeNewswire Inc

Nov 10, 2021

06:20PM EST Clearside Biomedical Q3 EPS $(0.08), Inline, Sales $3.07M Beat $2.58M Estimate Benzinga

11:51AM EST Clearside Biomedical's Return On Capital Employed Insights Benzinga

08:23AM EST The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance Benzinga

04:09AM EST Earnings Scheduled For November 10, 2021 Benzinga

Nov 8, 2021

08:29AM EST The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Benzinga

Oct 28, 2021

07:05AM EDT Clearside Biomedical to Report Third Quarter 2021 Financial GlobeNewswire Inc

Oct 25, 2021

06:47AM EDT Bausch + Lomb And Clearside Biomedical Announce FDA Approval Of XIPERE For Suprachoroidal Use For Treatment Of Macular Edema Associated With Uveitis Benzinga

06:47AM EDT Bausch + Lomb,Clearside Biomedical: FDA Approves XIPERE For Suprachoroidal Use For Macular Edema Associated With Uveitis RTTNews

06:45AM EDT (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis PR Newswire

Oct 13, 2021

07:05AM EDT Clearside Biomedical Delivers Podium and Poster Presentations at GlobeNewswire Inc

Oct 10, 2021

11:59AM EDT The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations and IPOs Take Center Stage Benzinga

Oct 4, 2021

07:12AM EDT Clearside Biomedical Highlights Poster Presentations At Retina Society 54th Annual Scientific Meeting Sept. 29 To Oct. 2 Benzinga

07:05AM EDT Clearside Biomedical, Inc.(NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that multiple presentations were given at the Retina Society 54th Annual Scientific Meeting which took place September 29 October 2, 2021 in Chicago, IL. GlobeNewswire Inc

Oct 3, 2021

02:21PM EDT The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs and More Benzinga

Oct 1, 2021

07:56AM EDT The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO Benzinga

Sep 21, 2021

10:47AM EDT How Good Are Clearside Biomedical's Earnings? | Return On Capital Employed Benzinga

07:13AM EDT Clearside Biomedical Announces Completion Of Dosing In Cohort 2 Of Phase 1/2a Trial Of CLS-AX In Wet AMD Patients RTTNews

07:13AM EDT Clearside Biomedical Announces Completion Of Dosing In Cohort 2 Of Phase 1/2a Clinical Trial Of CLS-AX In Wet AMD Patients Benzinga

07:05AM EDT Clearside Biomedical Announces Completion of Dosing in Cohort 2 of GlobeNewswire Inc

Sep 9, 2021

07:10AM EDT Clearside Biomedical Expands XIPERE License Agreement With Arctic Vision To Include Australia, New Zealand, India And ASEAN Countries Benzinga

07:05AM EDT Clearside Biomedical Expands XIPERE License GlobeNewswire Inc

Sep 2, 2021

08:20AM EDT The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab Benzinga

Aug 31, 2021

08:15AM EDT The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical Benzinga

Aug 23, 2021

04:05PM EDT Clearside Biomedical to Present at the Ophthalmology Futures GlobeNewswire Inc

Aug 15, 2021

09:49PM EDT Arctic Vision Expands License Territory For Suprachoroidal Space Injection Therapy ARVN001 To Include ASEAN Countries RTTNews

08:00PM EDT Arctic Vision Announces Expansion of License Territory for Suprachoroidal Space PR Newswire

Aug 10, 2021

05:11PM EDT Clearside Biomedical: Q2 Earnings Insights Benzinga

04:20PM EDT Clearside Biomedical Q2 EPS $(0.11) Beats $(0.12) Estimate, Sales $800.00K Beat $690.00K Estimate Benzinga

02:42PM EDT The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs Benzinga

07:55AM EDT The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts Benzinga

04:05AM EDT Earnings Scheduled For August 10, 2021 Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 4, 2021

07:05AM EDT Clearside Biomedical to Participate in Two Upcoming Investor GlobeNewswire Inc

Jul 29, 2021

10:39AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 29, 2021 Benzinga

06:22AM EDT HC Wainwright & Co. Initiates Coverage On Clearside Biomedical with Buy Rating, Announces Price Target of $10 Benzinga

Jul 27, 2021

04:05PM EDT Clearside Biomedical to Report Second Quarter 2021 Financial GlobeNewswire Inc

Jul 7, 2021

07:41AM EDT The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend Benzinga

Jun 18, 2021

07:46AM EDT The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs Benzinga

Jun 17, 2021

02:33PM EDT Mid-Afternoon Market Update: Nasdaq Gains Over 100 Points; CureVac Shares Plummet Benzinga

12:09PM EDT Mid-Day Market Update: Gold Drops Over 4%; Midatech Pharma Shares Jump Benzinga

10:19AM EDT Shares of biopharmaceutical company Clearside Biomedical, Inc. (CLSD) are trading up 28 percent on Thursday. The stock has been on an upward trajectory ever since it announced positive safety results from an early-stage trial for the treatment of a chronic eye disorder earlier this week. RTTNews

09:22AM EDT Wedbush Maintains Outperform on Clearside Biomedical, Raises Price Target to $18 Benzinga

Jun 16, 2021

08:20AM EDT The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO Benzinga

05:02AM EDT 44 Biggest Movers From Yesterday Benzinga

Jun 15, 2021

02:56PM EDT Mid-Afternoon Market Update: Nasdaq Down 100 Points; Clearside Biomedical Shares Spike Higher Benzinga

12:46PM EDT Shares of Clearside Biomedical, Inc. (CLSD) are gaining over 27% on Tuesday morning after the biopharmaceutical company announced positive safety results from a early-stage trial for the treatment of a chronic eye disorder. RTTNews

12:03PM EDT Mid-Day Market Update: Crude Oil Rises 1%; Sage Therapeutics Shares Slide Benzinga

11:55AM EDT JMP Securities Maintains Market Outperform on Clearside Biomedical, Raises Price Target to $9 Benzinga

11:49AM EDT Clearside Biomedical Shares Up 31%; JP Morgan Raises Price Target From $8 To $9 Benzinga

10:18AM EDT Mid-Morning Market Update: Markets Open Lower; US Retail Sales Drop 1.3% In May Benzinga

07:10AM EDT Clearside Biomedical Announces Positive Results From Cohort 1 Of OASIS Phase 1/2a Clinical Trial Of CLS-AX In Wet AMD RTTNews

07:09AM EDT Clearside Biomedical Announces Safety Results From Cohort 1 Of OASIS Phase 1/2a Clinical Trial Of CLS-AX In Wet AMD; Primary Endpints In Cohort 1 Were Achieved Benzinga

07:05AM EDT - CLS-AX 0.03 mg dose delivered via suprachoroidal injection was well-tolerated with no treatment related adverse events - GlobeNewswire Inc

Jun 9, 2021

07:05AM EDT Clearside Biomedical to Participate in Two Upcoming Investor GlobeNewswire Inc

Jun 2, 2021

07:25AM EDT Bausch Health And Clearside Biomedical Announce FDA Filing Acceptance For XIPERE; Assigns PDUFA Action Date Of Oct 30 RTTNews

07:00AM EDT Bausch Health And Clearside Biomedical Announce U.S. FDA Filing Acceptance For XIPERE Benzinga

06:59AM EDT Bausch Health And Clearside Biomedical Announce U.S. FDA Filing Acceptance For PR Newswire

May 17, 2021

04:36PM EDT Recap: Clearside Biomedical Q1 Earnings Benzinga

04:14PM EDT Clearside Biomedical Q1 EPS $(0.13) Misses $(0.10) Estimate Benzinga

04:05PM EDT Clearside Biomedical Announces First Quarter GlobeNewswire Inc

04:10AM EDT Earnings Scheduled For May 17, 2021 Benzinga

May 10, 2021

07:05AM EDT Clearside Biomedical Announces Multiple Poster Presentations at GlobeNewswire Inc

May 4, 2021

07:05AM EDT Clearside Biomedical to Report First Quarter 2021 Financial GlobeNewswire Inc

May 3, 2021

07:19AM EDT Clearside Biomedical Announces Resubmission Of New Drug Application For XIPERE For Treatment Of Macular Edema Associated With Uveitis Benzinga

07:12AM EDT Clearside Biomedical Announces Resubmission Of NDA For XIPERE For Treatment Of Macular Edema Associated With Uveitis RTTNews

07:05AM EDT Clearside Biomedical Announces Resubmission of New Drug GlobeNewswire Inc

Apr 5, 2021

07:05AM EDT Clearside Biomedical, Inc.(NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will present at two upcoming virtual conferences in April 2021: GlobeNewswire Inc

Mar 24, 2021

08:59AM EDT The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping Benzinga

Mar 10, 2021

04:10PM EST Clearside Biomedical Q4 EPS $(0.14) Misses $(0.11) Estimate, Sales $11.00K Miss $1.29M Estimate Benzinga

04:05PM EST - OASIS Wet AMD Phase 1/2a Trial Initiated and Cohort 1 Dosing Completed - GlobeNewswire Inc

07:26AM EST The Daily Biotech Pulse: MediciNova Bags BARDA Contract, Lilly's COVID-19 Antibody Cocktail Data, Bluebird Bio Refutes Blood Cancer Link Benzinga

04:04AM EST Earnings Scheduled For March 10, 2021 Benzinga

Mar 6, 2021

10:58AM EST The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings Benzinga

Mar 4, 2021

08:12AM EST The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company Benzinga

Mar 2, 2021

07:39AM EST Clearside Biomedical Announces Completion of Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX for the Treatment of Wet AMD Benzinga

07:14AM EST Clearside Biomedical Complets Patient Dosing In First Cohort Of Phase 1/2a Clinical Trial Of CLS-AX For Wet AMD RTTNews

07:05AM EST Clearside Biomedical Announces Completion of Patient Dosing in GlobeNewswire Inc

Feb 24, 2021

07:05AM EST Clearside Biomedical to Report Fourth Quarter and Full Year 2020 GlobeNewswire Inc

Feb 23, 2021

07:05AM EST Clearside Biomedical, Inc.(NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that the Company will participate in two upcoming investor conferences in March 2021: GlobeNewswire Inc

Feb 16, 2021

07:11AM EST Clearside Biomedical Announces CLS-AX Presentation Delivered at Angiogenesis, Exudation, and Degeneration 2021 Program Benzinga

07:05AM EST Clearside Biomedical Announces CLS-AX (axitinib injectable GlobeNewswire Inc

Feb 8, 2021

07:05AM EST - Proprietary suprachoroidal injection platform demonstrates broad applicability across multiple retinal disorders - GlobeNewswire Inc

Jan 20, 2021

07:32AM EST The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study Benzinga

Jan 15, 2021

07:57AM EST The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges Benzinga

Jan 12, 2021

07:28AM EST Clearside Biomedical Says First Patients Enrolled In Phase 1/2a Clinical Trial Of CLS-AX RTTNews

07:14AM EST Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD Benzinga

07:05AM EST Clearside Biomedical Announces First Patients Enrolled in Phase GlobeNewswire Inc

Jan 8, 2021

07:25AM EST The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs Benzinga

Jan 7, 2021

09:51AM EST Clearside Biomedical, Inc.: WHITMORE BRADFORD T (10%+) Buys 350,750 @ Avg Price: $2.85 (Form4) Benzinga

Jan 6, 2021

07:11AM EST Clearside Biomedical Enters Deal For Purchase And Sale Of 4.21 Mln Shares At $2.851/Shr Priced At-the-market RTTNews

07:05AM EST Clearside Biomedical Announces Pricing of $12 Million Registered GlobeNewswire Inc

Jan 5, 2021

05:28PM EST Clearside Biomedical Reported That From Oct. 1, 2020 To Jan. 4, 2021, The Co. Sold 4.5M Shares Pursuant To At-The-Market Sales Agreement For Net Proceeds Of $9.4M Benzinga

Dec 28, 2020

10:40AM EST Clearside Biomedical 10%+ Owner Brad Whitmore Buys 51,195 @ Avg Price: $1.95 Benzinga

Nov 17, 2020

05:39AM EST Clearside Biomedical 10%+ Owner Bradford T Whitmore Reported Purchase of 62,000 Shares @ Avg Price of $1.69/Share in Form 4 Filing on Monday Benzinga

Nov 16, 2020

07:05AM EST Clearside Biomedical, Inc.(Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that two presentations of Clearside preclinical and clinical data were given at the virtual American Academy Ophthalmology (AAO) 2020 Annual Meeting. GlobeNewswire Inc

Nov 11, 2020

07:05AM EST Clearside Biomedical, Inc.(NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Management will present a company overview at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020 at 8:40 a.m. ET. GlobeNewswire Inc

Nov 10, 2020

04:36PM EST Clearside Biomedical Q3 EPS $(0.05) Beats $(0.12) Estimate, Sales $3.43M Beat $1.82M Estimate Benzinga

04:05PM EST - Initiation of Phase 1/2a Trialof CLS-AX (axitinib injectable suspension) for Wet Age-Related Macular DegenerationExpected by Year-End 2020 -- Phase 2 TrialsUsing SCS MicroinjectorOngoingbyGene Therapy and Oncology Partners --Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - GlobeNewswire Inc

08:40AM EST The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Oct 30, 2020

07:05AM EDT Clearside Biomedical to Report Third Quarter 2020 Financial GlobeNewswire Inc

Sep 23, 2020

07:05AM EDT Clearside Biomedical, Inc.(Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today several clinical data presentations were given at the virtual 53rd Annual Scientific Meeting of The Retina Society. GlobeNewswire Inc

Sep 11, 2020

08:35AM EDT Clearside Biomedical Reports Its Oncology Licensing Partner Doses First Patient In Phase 2 Study In Patients With Choroidal Melanoma Using SCS Microinjector For Suprachoroidal Delivery Benzinga

08:30AM EDT Clearside Biomedicals Oncology Licensing Partner GlobeNewswire Inc

Sep 9, 2020

04:05PM EDT Clearside Biomedical to Present at the Virtual H.C. Wainwright GlobeNewswire Inc

08:34AM EDT Clearside Biomedical Licensing Partner REGENXBIO Doses First Patient In Phase 2 Gene Therapy Trial Using SCS Microinjector For Suprachoroidal Delivery Benzinga

08:30AM EDT Clearside Biomedicals Licensing Partner Doses GlobeNewswire Inc

Aug 26, 2020

07:07AM EDT Clearside Biomedical Announces Three Additional Patents In US And Europe Benzinga

07:05AM EDT Clearside Biomedical, Inc.(NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today the recent issuance of three additional patents in the United States and Europe. GlobeNewswire Inc

Aug 11, 2020

11:35AM EDT Clearside Biomedical shares are trading higher after the company reported Q2 EPS and sales results were up year over year. The company also announced the FDA has accepted its investigational new drug application for CLS-AX administered in Suprachoroidal Space. Benzinga

Aug 10, 2020

04:43PM EDT Clearside Biomedical Q2 EPS $(0.13) Up From $(0.15) YoY, Sales $354.00K Up From $45.00K YoY Benzinga

04:34PM EDT Clearside Biomedical Announces U.S. FDA Acceptance of Investigational New Drug Application for CLS-AX Administered in Suprachoroidal Space Benzinga

04:05PM EDT - IND Accepted by FDA for Suprachoroidal CLS-AX (axitinib injectable suspension) -- Expanded Internal Suprachoroidal Pipeline with Two New Preclinical Programs -- Engaged New Contract Manufacturer for XIPERE -- Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - GlobeNewswire Inc

04:02PM EDT - Initiation of CLS-AX Phase 1/2a Clinical Trial in Wet AMD Targeted by Year-End 2020 - GlobeNewswire Inc

04:10AM EDT Earnings Scheduled For August 10, 2020 Benzinga

Aug 4, 2020

07:05AM EDT Clearside Biomedical to Present at the 2020 Wedbush PacGrow GlobeNewswire Inc

Jul 30, 2020

07:05AM EDT Clearside Biomedical to Report Second Quarter 2020 Financial GlobeNewswire Inc

Jul 27, 2020

07:05AM EDT Clearside Biomedical Announces Multiple Presentations at the ASRS GlobeNewswire Inc

Share